Overview

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Status:
Completed
Trial end date:
2018-05-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibrosis and severe anemia not receiving RBC-transfusions (China extension study only)
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Pomalidomide
Thalidomide